Pharmaceutical manufacturers continue to face significant challenges understanding what affiliated fees actually buy within pharmacy benefit manager contracting structures. A Federal Trade Commission settlement with Express Scripts, announced on February 4, 2026,
MoreAbbVie (ABBV) and the PGA Tour have announced a landmark partnership, naming the pharmaceutical giant the Official Pharmaceutical Sponsor of the PGA Tour and the 2026 Presidents Cup. The centrepiece of the
MoreBioMarin Pharmaceutical has announced it is discontinuing development of Voxzogo for children with Noonan syndrome, marking another setback for the drug’s expansion ambitions. The company said the decision followed an assessment of
MoreSanofi (SNY) and Cheplapharm have announced a strategic partnership that will see the French pharmaceutical giant transfer 20 mature medicines to the German company. As part of the agreement, Cheplapharm will also
MoreTeva Pharmaceutical Industries (TEVA) has begun trading its ordinary shares directly on the New York Stock Exchange, marking a significant milestone for the global drugmaker. The move represents a key step in
MoreNovo Nordisk is streamlining its public identity, adopting “Novo” as its everyday brand name while retaining Novo Nordisk A/S as its legal global company name. The move places the Danish pharmaceutical giant
MoreScholar Rock has secured FDA approval for Isembyld (apitegromab-mstn), a first-of-its-kind treatment targeting muscle loss in spinal muscular atrophy patients. The approval covers adults and paediatric patients aged two years and older
MoreGSK has announced plans to shut down its flu vaccine manufacturing facility in Dresden, Germany, with the closure scheduled for the summer of 2027. The British pharmaceutical giant cited falling demand for
MoreThe U.S. biopharmaceutical market is no longer operating under a single dominant economic model, according to industry analyst Bill Roth. Writing in the final instalment of his Great Repricing series, Roth argues
MoreGSK secured FDA approval for Jideytro, known scientifically as zidesamtinib, marking the British pharmaceutical giant’s first-ever commercial lung cancer treatment. The approval came roughly two months ahead of the FDA’s original target
More
